ANI Pharmaceuticals, Inc. $ANIP Shares Acquired by AlphaQuest LLC

AlphaQuest LLC lifted its position in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) by 1,602.7% during the fourth quarter, HoldingsChannel reports. The fund owned 26,784 shares of the specialty pharmaceutical company’s stock after acquiring an additional 25,211 shares during the quarter. AlphaQuest LLC’s holdings in ANI Pharmaceuticals were worth $2,114,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds have also made changes to their positions in the company. Hantz Financial Services Inc. increased its stake in shares of ANI Pharmaceuticals by 70.3% during the fourth quarter. Hantz Financial Services Inc. now owns 603 shares of the specialty pharmaceutical company’s stock worth $48,000 after acquiring an additional 249 shares during the period. Mizuho Markets Americas LLC boosted its holdings in ANI Pharmaceuticals by 11.9% during the fourth quarter. Mizuho Markets Americas LLC now owns 201,994 shares of the specialty pharmaceutical company’s stock worth $15,945,000 after buying an additional 21,416 shares in the last quarter. LSV Asset Management purchased a new stake in ANI Pharmaceuticals during the fourth quarter worth about $695,000. Kingdom Financial Group LLC. purchased a new stake in ANI Pharmaceuticals during the fourth quarter worth about $141,000. Finally, Mitsubishi UFJ Asset Management UK Ltd. boosted its holdings in ANI Pharmaceuticals by 62.5% during the fourth quarter. Mitsubishi UFJ Asset Management UK Ltd. now owns 13,000 shares of the specialty pharmaceutical company’s stock worth $1,026,000 after buying an additional 5,000 shares in the last quarter. 76.05% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other news, CFO Stephen P. Carey sold 7,312 shares of the business’s stock in a transaction that occurred on Thursday, March 5th. The shares were sold at an average price of $75.50, for a total value of $552,056.00. Following the completion of the transaction, the chief financial officer owned 185,543 shares of the company’s stock, valued at $14,008,496.50. The trade was a 3.79% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Patrick D. Walsh sold 10,000 shares of the company’s stock in a transaction that occurred on Wednesday, May 13th. The stock was sold at an average price of $80.63, for a total transaction of $806,300.00. Following the transaction, the director directly owned 38,432 shares of the company’s stock, valued at $3,098,772.16. This trade represents a 20.65% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders have sold 91,427 shares of company stock valued at $7,089,066. 8.10% of the stock is currently owned by insiders.

ANI Pharmaceuticals Stock Performance

NASDAQ:ANIP opened at $81.41 on Wednesday. The firm has a 50 day simple moving average of $78.32 and a 200-day simple moving average of $79.85. The company has a debt-to-equity ratio of 1.06, a current ratio of 3.12 and a quick ratio of 2.52. The firm has a market cap of $1.85 billion, a PE ratio of 20.61 and a beta of 0.46. ANI Pharmaceuticals, Inc. has a 1-year low of $57.33 and a 1-year high of $99.50.

ANI Pharmaceuticals (NASDAQ:ANIP) last posted its quarterly earnings data on Friday, May 8th. The specialty pharmaceutical company reported $2.05 earnings per share for the quarter, beating analysts’ consensus estimates of $1.28 by $0.77. The business had revenue of $237.46 million during the quarter, compared to analyst estimates of $207.63 million. ANI Pharmaceuticals had a net margin of 9.98% and a return on equity of 27.51%. The company’s revenue was up 20.5% on a year-over-year basis. During the same quarter in the previous year, the business posted $1.70 earnings per share. ANI Pharmaceuticals has set its FY 2026 guidance at 9.190-9.690 EPS. On average, equities analysts expect that ANI Pharmaceuticals, Inc. will post 7.73 EPS for the current year.

Analysts Set New Price Targets

A number of analysts recently commented on the stock. Wall Street Zen raised shares of ANI Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Saturday, May 9th. Zacks Research downgraded shares of ANI Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Thursday, May 14th. Five research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $107.33.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI’s product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.